Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.
Heron Therapeutics, Inc. (Nasdaq: HRTX) is a leading commercial-stage biotechnology company focused on enhancing patient care through the development and commercialization of innovative therapeutic solutions. Specializing in the use of its proprietary Biochronomer™ polymer-based drug delivery platform, Heron is revolutionizing the pharmaceutical landscape by converting daily injectable drugs into weekly or bi-weekly regimens.
The company's product portfolio includes APONVIE, SUSTOL, ZYNRELEF, and CINVANTI, which target unmet medical needs in both acute care and oncology settings. APONVIE is effective in preventing postoperative nausea and vomiting, offering a quick 30-second IV push that is bioequivalent to oral aprepitant. SUSTOL utilizes Heron's Biochronomer® technology to extend therapeutic levels of granisetron for over five days, aiding in the prevention of chemotherapy-induced nausea and vomiting (CINV).
ZYNRELEF, a dual-acting local anesthetic combining bupivacaine and meloxicam, is notably the first extended-release local anesthetic demonstrating superior pain management and reducing opioid use for up to 72 hours post-surgery. Originally approved by the FDA in May 2021, its indication was expanded in January 2024 to cover various soft tissue and orthopedic surgeries. Recently, Heron submitted a Prior Approval Supplement (PAS) for a Vial Access Needle to streamline ZYNRELEF's preparation process, potentially enhancing its adoption in clinical settings.
CINVANTI, an IV formulation of aprepitant, significantly reduces both acute and delayed phases of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy, improving overall patient quality of life during treatment.
Financially, Heron Therapeutics is on a robust trajectory, having implemented a cost reduction program projected to save approximately $75 million through 2025. The company has secured $30 million in equity financing and a $50 million working capital facility, aiming to achieve profitability with its current operational strategies.
Heron’s strong focus on clinical excellence and strategic partnerships, such as its recent collaboration with CrossLink Life Sciences to expand ZYNRELEF's sales network, underscores its commitment to delivering substantial value and improving patient outcomes. For more detailed information, visit herontx.com.
Heron Therapeutics (HRTX) reported Q3 2022 financials, showing strong net product sales growth. ZYNRELEF's sales reached $2.7 million, reflecting an 18% quarterly demand increase. The oncology care franchise achieved net sales of $23.9 million, up 13% year-over-year, sustaining a projected $93 million to $95 million for full-year 2022. APONVIE received FDA approval, with U.S. launch expected in Q1 2023, targeting postoperative nausea and vomiting. Despite a net loss of $41.9 million, improvements in operating cash usage were noted.
Heron Therapeutics, Inc. (Nasdaq: HRTX) will host a conference call and webcast on November 8, 2022, at 4:30 p.m. ET, to discuss its third quarter 2022 financial results and recent business highlights. Investors can join the call by dialing (646) 307-1963 for domestic calls or (800) 715-9871 for international calls, using the passcode 4433557. The event will also be available via webcast on Heron's website, with an archived version accessible for 60 days post-event.
Heron Therapeutics has received FDA approval for APONVIE (aprepitant), the first intravenous formulation for preventing postoperative nausea and vomiting (PONV) in adults. Administered as a single 30-second IV injection, APONVIE achieves therapeutic levels rapidly and maintains them for at least 48 hours. Clinical studies showed APONVIE was more effective than standard treatments, reducing vomiting in patients post-surgery. This launch expands Heron's acute care portfolio, targeting approximately 36 million surgical procedures annually in the U.S.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced a private placement to raise approximately $76.5 million by selling 16,129,032 shares of common stock at $3.10 per share. This funding, led by Deep Track Capital, LP, aims to support the company's acute care and oncology franchises, including the anticipated launch of HTX-019 for postoperative nausea and vomiting. The placement is expected to close on August 11, 2022. The company also plans to file a registration statement with the SEC for the resale of these shares.
Heron Therapeutics reported significant growth in the second quarter of 2022, with ZYNRELEF product sales soaring by 140% sequentially, reaching $2.5 million. The oncology care franchise saw net sales climb 12% to $25.1 million, prompting an increase in full-year sales guidance to $93 million to $95 million. The company anticipates over $50 million in cost reductions due to restructuring efforts. Pro-forma cash post-private placement stands at $158.7 million, ensuring a cash runway through 2024.
Heron Therapeutics (HRTX) will host a conference call on August 9, 2022, at 8:30 a.m. ET to discuss its second quarter 2022 financial results and recent business developments. The call is accessible via phone or webcast, with an archive available for 60 days post-call. Heron focuses on developing therapeutic innovations to enhance medical care, particularly for acute care and oncology patients. Interested parties can find more details on the company's website.
Heron Therapeutics, Inc. (HRTX) announced a study published in the Journal of Knee Surgery evaluating the safety and efficacy of ZYNRELEF as part of a non-opioid multimodal analgesic regimen for total knee arthroplasty (TKA). The study found over 80% of patients did not experience severe pain post-surgery, with 12% remaining opioid-free. ZYNRELEF demonstrated improved pain control compared to standard treatments, showing no safety concerns. The company emphasizes the need for controlled trials to confirm these promising results and maintain ZYNRELEF's potential in outpatient settings.
Heron Therapeutics, Inc. (Nasdaq: HRTX) announced its participation in the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 8:30 am ET. The event runs from June 8-10 in New York, NY. A live webcast will be available on their website under the Investor Resources section. Heron focuses on developing therapeutic innovations to enhance medical care for patients, particularly in acute care and oncology.
Heron Therapeutics (HRTX) presented interim data from a Phase 2 study of ZYNRELEF at the SOAP 54th Annual Meeting. ZYNRELEF, approved for postoperative analgesia, showed low levels of bupivacaine and meloxicam in breast milk post-administration in women undergoing C-sections. Results indicated ZYNRELEF was well-tolerated and effectively reduced postoperative opioid use, with 27% of patients experiencing opioid-free recovery. The findings suggest ZYNRELEF could significantly enhance pain management for postpartum women while minimizing opioid exposure.
FAQ
What is the current stock price of Heron Therapeutics (HRTX)?
What is the market cap of Heron Therapeutics (HRTX)?
What products does Heron Therapeutics offer?
What is ZYNRELEF used for?
What recent financial initiatives has Heron Therapeutics undertaken?
What is the Biochronomer™ platform?
What are the recent corporate updates from Heron Therapeutics?
When was ZYNRELEF first approved by the FDA?
What is APONVIE used for?
What steps has Heron taken to achieve profitability?
How does SUSTOL help cancer patients?
Where can I find more information about Heron Therapeutics?
